20 articles
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
A completed Phase 3 trial evaluated whether the anti-TNF biologic infliximab safely and effectively treats plaque psoriasis.
A new in vitro study shows Thymosin ฮฑ1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
A landmark 48-RCT Cochrane review finds high-certainty evidence that convalescent plasma does not reduce death in moderate-to-severe COVID-19.
Advanced photon-counting CT technology reveals arterial inflammation in giant cell arteritis with superior clarity.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
Scientists discover how blocking CD40-CD40L pathway reduces dangerous clotting in antiphospholipid syndrome patients.
A 2025 meta-analysis of 11 RCTs finds Tฮฑ1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
Mice lacking the PERP apoptosis gene develop faulty thymic immune screening, accumulating self-reactive T-cells that trigger arthritis as they age.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
Machine learning analyzes blood proteins to identify lupus before clinical diagnosis, potentially revolutionizing early detection.
Clinical trial results for oral icotrokinra in treating plaque psoriasis across adult and adolescent patients published in NEJM.
A major Cochrane network meta-analysis protocol aims to compare and rank interventions for preeclampsia prevention before 17 weeks gestation.
A Stanford RCT finds pulsed electromagnetic field therapy significantly reduces thumb CMC osteoarthritis pain at 6 weeks, even after treatment ends.
Large Hong Kong registry study tracked how well patients stayed on newer JAK inhibitors versus traditional TNF blockers for RA treatment.
